Last reviewed · How we verify
LY293111
At a glance
| Generic name | LY293111 |
|---|---|
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- LY293111 in Treating Patients With Advanced Solid Tumors (PHASE1)
- A Study With Gemcitabine, Cisplatin, and LY293111 in Non-Small Cell Lung Cancer (PHASE2)
- A Study With LY293111, Gemcitabine and Placebo in Patients With Pancreatic Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY293111 CI brief — competitive landscape report
- LY293111 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI